Compare
Oncotelic Therapeutics, Inc. vs Erasca, Inc. vs Ironwood Pharmaceuticals Inc vs Tango Therapeutics, Inc.
| Latest fiscal year | Oncotelic Therapeutics, Inc. OTLC | Erasca, Inc. ERAS | Ironwood Pharmaceuticals Inc IRWD | Tango Therapeutics, Inc. TNGX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | $296.15M | $62.38M |
| Revenue growth (YoY) | n/a | n/a | -15.7% | +48.3% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | 33.3% | -178.4% |
| Net margin | n/a | n/a | 8.1% | -162.9% |
| Net income | $249.28M | -$124.55M | $24.02M | -$101.59M |
| EPS (Diluted) | $0.59 | -$0.44 | $0.15 | -$0.87 |
| Operating cash flow | -$1.38M | -$95.45M | $127.04M | -$138.89M |
| Free cash flow | n/a | -$95.58M | $127.01M | -$139.93M |
| Cash & equivalents | n/a | $73.81M | $215.46M | $112.28M |
| Total assets | $393.09M | $396.15M | $396.90M | $398.69M |
| Total liabilities | $131.36M | $70.98M | n/a | $52.51M |
| Shareholders' equity | $262.76M | $325.17M | -$261.83M | $346.18M |
| Return on year-end equity | 94.9% | -38.3% | n/a | -29.3% |
| Shares outstanding | 442.60M | 284.16M | 163.06M | 135.94M |
Revenue, most recent five fiscal years
| Fiscal year | Oncotelic Therapeutics, Inc. | Erasca, Inc. | Ironwood Pharmaceuticals Inc | Tango Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $70.0K Ended 2023-12-31 | n/a | $296.15M Ended 2025-12-31 | $62.38M Ended 2025-12-31 |
| 1 year earlier | n/a | n/a | $351.41M Ended 2024-12-31 | $42.07M Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $442.74M Ended 2023-12-31 | $36.53M Ended 2023-12-31 |
| 3 years earlier | $1.74M Ended 2020-12-31 | n/a | $410.60M Ended 2022-12-31 | $24.86M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $413.75M Ended 2021-12-31 | $37.04M Ended 2021-12-31 |